RELA divergent transcript (RELA-DT)

The RELA divergent transcript refers to a long non-coding RNA produced from divergent (bidirectional) transcription initiation at the promoter of the RELA gene (encoding the NF-κB p65 subunit). Divergent transcription is a widespread genomic phenomenon in which RNA polymerase II initiates transcription in both sense and antisense directions from promoter regions, often yielding a non-coding transcript opposite the protein-coding gene[1][2]. These non-coding RNAs typically have low stability and are subject to rapid degradation, with only a minority accumulating to detectable steady-state levels. There is extensive evidence that such lncRNAs may be co-regulated with their associated protein-coding genes and may play roles in gene regulation or chromatin modification, but there is no specific evidence or functional annotation for a RELA-specific divergent transcript being a therapeutic target, biomarker, or drug-interaction partner[1][2]. If you seek a *therapeutic target*, "RELA" (NF-κB p65) itself is a validated transcription factor involved in many immune and inflammatory pathways; the "divergent transcript" form (RELA-DT) is not considered a target based on current data[1][2].